Prostate Cancer Clinical Trial
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Summary
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Eligibility Criteria
Inclusion Criteria:
Must have histologically or cytologically confirmed adenocarcinoma of the prostate
Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
Prior treatment with an androgen receptor (AR) degrader
Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Boston Massachusetts, 02215, United States More Info
Contact
New York New York, 10029, United States
Philadelphia Pennsylvania, 19104, United States
San Antonio Texas, 78229, United States More Info
Madison Wisconsin, 53705, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?